Keyphrases
Antiangiogenic Activity
100%
Anticancer Agents
100%
Pigment Epithelium-derived Factor
100%
Phosphomimetic
100%
Vascular Endothelial Growth Factor
27%
Endothelial Cells
18%
Neovascularization
18%
Bevacizumab
18%
Endothelial Cell Apoptosis
18%
Tumor
9%
Cancer Cells
9%
Phosphorylation
9%
Physiological Function
9%
Solid Tumors
9%
Angiogenesis Inhibitors
9%
Cells in Culture
9%
Endogenous Inhibitor
9%
Antitumor Activity
9%
Colon Cancer
9%
Breast Cancer
9%
Xenograft Model
9%
MDA-MB-231
9%
Tumor Growth
9%
Vascular Network
9%
Basic Fibroblast Growth Factor (bFGF)
9%
Phosphorylation State
9%
Immunohistochemical Analysis
9%
U87MG
9%
Mouse Tumor Model
9%
Antiangiogenic Agents
9%
Antitumor Effect
9%
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
9%
Preclinical Development
9%
HCT116
9%
Glioblastoma Xenografts
9%
Biochemistry, Genetics and Molecular Biology
Photosynthetic Pigment
100%
Anticancer
100%
Antiangiogenic Activity
100%
Phosphomimetics
100%
Wild Type
27%
Vascular Endothelial Growth Factor
18%
Neovascularization (Pathology)
18%
Bevacizumab
18%
Programmed Cell Death
18%
Angiogenesis
9%
Colon
9%
Cancer Cell
9%
Tumor Progression
9%
Growth Inhibition
9%
Antineoplastic Activity
9%
Preclinical Study
9%
Kinase Insert Domain Receptor
9%
Basic Fibroblast Growth Factor
9%
Vascular Endothelial Growth Factor A
9%
U87
9%
Messenger RNA
9%
Cancer Model
9%
Pharmacology, Toxicology and Pharmaceutical Science
Antiangiogenic
100%
Pigment Epithelium Derived Factor
100%
Anticancer Drug
100%
Neovascularization (Pathology)
18%
Vasculotropin
18%
Bevacizumab
18%
Neoplasm
9%
Anticarcinogen
9%
Malignant Neoplasm
9%
Solid Malignant Neoplasm
9%
Cancer Model
9%
Breast Cancer
9%
Antitumor Activity
9%
Vasculotropin A
9%
Tumor Growth
9%
Glioblastoma
9%
Colon Carcinoma
9%
Vasculotropin Receptor 2
9%
Angiogenesis Inhibitor
9%
Fibroblast Growth Factor 2
9%
Messenger RNA
9%
Immunology and Microbiology
Antiangiogenic Activity
100%
Pigment Epithelium Derived Factor
100%
Wild Type
27%
Vasculotropin
18%
Bevacizumab
18%
Neovascularization (Pathology)
18%
Programmed Cell Death
18%
Colon
9%
Cancer Cell
9%
Angiogenesis
9%
Xenograft
9%
Antineoplastic Activity
9%
Growth Inhibition
9%
Preclinical Study
9%
Angiogenesis Inhibitor
9%
Kinase Insert Domain Receptor
9%
Fibroblast Growth Factor 2
9%
Vasculotropin A
9%